RECRUITING Phase 2 ClinicalTrials.gov

Randomised Controlled Trial Comparing CD62L and CD45RA Depleted Donor Lymphocyte Infusion With T-cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Sponsor: Hong Kong Children's Hospital • ClinicalTrials.gov ID: NCT07867769

Registry updated: 2026-10-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of clinical trial is to compare the efficacy and safety of CD62L depleted donor lymphocyte infusion (DLI) with CD45RA depleted DLI in children who receive T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT). Participants will be randomised to receive either CD62L depleted DLI or CD45RA depleted DLI with HSCT and evaluate for efficacy and safety outcomes.

Interventions

CD62L depleted DLI (Biological)
CD62L depleted DLI
CD45RA depleted DLI (Biological)
CD45RA depleted DLI
Haploidentical HSCT (Procedure)
T cell depleted haploidentical HSCT

Eligibility criteria

Inclusion Criteria: * Aged 0-18 years who requires allogeneic hematopoietic stem cell transplant, has no HLA-matched sibling donor but has an HLA-haploidentical donor. * Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy. * Karnofsky or Lansky performance status score ≥50 Exclusion Criteria: * Pregnant or lactating woman * HIV infection * Patients for whom alternative treatment is deemed more appropriate * Patients who are unlikely to benefit from haploidentical HSCT, e.g., terminal malignancy with multiorgan failure

Conditions

Hematopoietic Cell Transplantation

Locations

Hong Kong Children's Hospital — Hong Kong, Hong Kong

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment